Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice
Thrombosis and Haemostasis · 01.01.2025 · 125 (01) · 021-032
DOI: 10.1055/a-2315-8199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.01.2025. Verfasst von Kazuki Shimizu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Monoclonal, Humanized, Antibodies, Bispecific, Blood Coagulation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology (MEXT).
Abstract (Originalsprache)
Background
Bypassing agents are used for breakthrough bleedings in patients with hemophilia A with inhibitor (PwHAwI) receiving emicizumab prophylaxis. Previous study demonstrated a weak binding affinity between emicizumab and factor (F)X (K d; 1.85 μM), and that this value was much greater than the plasma FX concentration (∼130 nM). We speculated that increased FX levels could enhance coagulation potential in emicizumab-treated patients with hemophilia A (PwHA). To investigate the relationship between FX concentrations and emicizumab-driven coagulation.
Methods
Plasma FX (up to 1,040 nM) and emicizumab (50 µg/mL) were added to FVIII-deficient plasmas, and plasma-derived FX (520 nM) or recombinant (r)FVIIa (2.2 µg/mL) was added to plasmas from three emicizumab-treated PwHAwI. The adjusted maximum coagulation velocity (Ad|min1|) by clot waveform analysis and peak thrombin (PeakTh) by thrombin generation assay in them were evaluated. Emicizumab (3.0 mg/kg), human (h)FIX (100 IU/kg), and various doses of hFX (100–500 IU/kg) were intravenously administered to HA mice. Clotting time/clot formation time (CT/CFT) were assessed using rotational thromboelastometry, and blood loss was estimated by a tail-clip assay.
Results
The addition of FX to FVIII-deficient plasma with emicizumab increased Ad|min1| and PeakTh. The coagulation parameters in emicizumab-treated PwHAwI spiked with additional FX remained within the normal range as well as the additional rFVIIa. In animal models, hFX injection shortened the CT and CT + CFT. The shorter CT and CT + CFT, and the lower blood loss were evident after 200 or 500 IU/kg hFX administration, and those indices were comparable to those in wild-type mice.
Conclusion
Supplementation with FX may improve emicizumab-driven hemostasis in PwHA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
- Advanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Nara, Japan.
- Medical Affairs Section, KM Biologics Co., Ltd, Kumamoto, Japan.
Förderung
- Ministry of Education, Culture, Sports, Science and Technology (MEXT)
Zitieren
APA
Shimizu, K., Nakajima, Y., Takami, E., Nakano, H., & Nogami, K. (2025). Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice. Thrombosis and Haemostasis, 125(01), 021-032. https://doi.org/10.1055/a-2315-8199
Vancouver
Shimizu K, Nakajima Y, Takami E, Nakano H, Nogami K. Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice. Thrombosis and Haemostasis. 2025;125(01):021-032. doi:10.1055/a-2315-8199
BibTeX
@article{Shimizu2025,
author = {Shimizu, Kazuki and Nakajima, Yuto and Takami, Eisuke and Nakano, Hirotoshi and Nogami, Keiji},
title = {Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice},
journal = {Thrombosis and Haemostasis},
year = {2025},
volume = {125},
number = {01},
pages = {021--032},
doi = {10.1055/a-2315-8199}
}
EUVIMED